CLDX FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for Celldex Therapeutics in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($3.67) for the year, down from their prior estimate of ($3.61). Cantor Fitzgerald has a “Overweight” rating and a $67.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million.

A number of other equities research analysts also recently weighed in on CLDX. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $55.38.

Celldex Therapeutics Trading Up 1.1 %

CLDX stock opened at $21.33 on Thursday. The stock has a market cap of $1.42 billion, a P/E ratio of -8.30 and a beta of 1.76. The stock’s fifty day simple moving average is $23.48 and its two-hundred day simple moving average is $28.59. Celldex Therapeutics has a 1-year low of $18.61 and a 1-year high of $49.65.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in shares of Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after acquiring an additional 321,325 shares during the last quarter. Values First Advisors Inc. grew its position in Celldex Therapeutics by 20.0% in the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock worth $733,000 after buying an additional 4,837 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Celldex Therapeutics by 293.2% in the third quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock worth $958,000 after buying an additional 21,013 shares during the period. Bellevue Group AG grew its holdings in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after buying an additional 100,000 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Celldex Therapeutics in the 3rd quarter valued at approximately $871,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.